25 May 2013
Keywords: trimeris/roche, fuzeon, sales, leap, first, quarter, firm
Article | 25 April 2005
US firm Trimeris, the developer of the HIV/AIDS drug Fuzeon (enfuvirtide) which is sold by Switzerland's Roche, says that ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
25 April 2005
24 May 2013
© 2013 thepharmaletter.com